ZA201202557B - Method for treating androgen receptor positive cancers - Google Patents
Method for treating androgen receptor positive cancersInfo
- Publication number
- ZA201202557B ZA201202557B ZA2012/02557A ZA201202557A ZA201202557B ZA 201202557 B ZA201202557 B ZA 201202557B ZA 2012/02557 A ZA2012/02557 A ZA 2012/02557A ZA 201202557 A ZA201202557 A ZA 201202557A ZA 201202557 B ZA201202557 B ZA 201202557B
- Authority
- ZA
- South Africa
- Prior art keywords
- androgen receptor
- receptor positive
- positive cancers
- treating androgen
- treating
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 102000001307 androgen receptors Human genes 0.000 title 1
- 108010080146 androgen receptors Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25439509P | 2009-10-23 | 2009-10-23 | |
| PCT/US2010/053916 WO2011050353A1 (en) | 2009-10-23 | 2010-10-25 | Method for treating androgen receptor positive cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201202557B true ZA201202557B (en) | 2013-06-26 |
Family
ID=43900720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2012/02557A ZA201202557B (en) | 2009-10-23 | 2012-04-10 | Method for treating androgen receptor positive cancers |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8835447B2 (https=) |
| EP (1) | EP2490531A4 (https=) |
| JP (1) | JP2013508417A (https=) |
| KR (1) | KR20120095402A (https=) |
| CN (1) | CN102573472A (https=) |
| AP (1) | AP2012006277A0 (https=) |
| AU (1) | AU2010310477A1 (https=) |
| BR (1) | BR112012009262A2 (https=) |
| CA (1) | CA2779309A1 (https=) |
| EA (1) | EA201290208A1 (https=) |
| GE (1) | GEP20146138B (https=) |
| IL (1) | IL219331A0 (https=) |
| MX (1) | MX2012004624A (https=) |
| WO (1) | WO2011050353A1 (https=) |
| ZA (1) | ZA201202557B (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011150360A1 (en) | 2010-05-28 | 2011-12-01 | The Board Of Regents Of The University Of Texas System | Oligo-benzamide compounds and their use |
| WO2013023300A1 (en) * | 2011-08-15 | 2013-02-21 | The University Of British Columbia | Inhibitors of androgen receptor activation function-2 (af2) as therapeutics and methods for their use |
| WO2013055793A1 (en) | 2011-10-12 | 2013-04-18 | University Of Pittsburg-Of The Commonwealth System Of Higher Education | Small molecules targeting androgen receptor nuclear localization and/or level in prostate cancer |
| US8754124B2 (en) | 2011-11-23 | 2014-06-17 | Board Of Regents, The University Of Texas System | Oligo-benzamide compounds and their use in treating cancers |
| WO2013078288A1 (en) * | 2011-11-23 | 2013-05-30 | The Board Of Regents Of The University Of Texas System | Oligo-benzamide compounds for use in treating cancers |
| EP2854809B1 (en) | 2012-06-01 | 2017-12-06 | Leibniz-Institut für Alternsforschung - Fritz-Lipmann-Institut e.V. (FLI) | Inhibitors of the notch signalling pathway and secretion for use in medicine |
| US10987334B2 (en) | 2012-07-13 | 2021-04-27 | University Of Tennessee Research Foundation | Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs) |
| US10314807B2 (en) | 2012-07-13 | 2019-06-11 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
| US9744149B2 (en) | 2012-07-13 | 2017-08-29 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
| PT2872482T (pt) * | 2012-07-13 | 2020-09-22 | Oncternal Therapeutics Inc | Método de tratamento de cancro de mama com modulador seletivo do recetor de andrógeno (sarm) |
| US9969683B2 (en) | 2012-07-13 | 2018-05-15 | Gtx, Inc. | Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS) |
| US10258596B2 (en) | 2012-07-13 | 2019-04-16 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
| US9622992B2 (en) | 2012-07-13 | 2017-04-18 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
| NZ740700A (en) * | 2012-07-27 | 2019-07-26 | Aragon Pharmaceuticals Inc | Methods and compositions for determining resistance to androgen receptor therapy |
| WO2014153043A1 (en) * | 2013-03-14 | 2014-09-25 | Health Research, Inc. | Compounds and methods for treating cancers |
| CA2924527C (en) | 2013-09-20 | 2022-07-12 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Compounds for treating prostate cancer |
| US20160257657A1 (en) | 2013-09-20 | 2016-09-08 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer |
| US10980806B2 (en) | 2016-03-24 | 2021-04-20 | University of Pittsburgh—of the Commonwealth System of Higher Education | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer |
| EP3487497B1 (en) * | 2016-07-21 | 2021-09-08 | Hadasit Medical Research Services and Development Ltd. | Combinations comprising ar antagonists or inhibitors for use in treating glioblastoma |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4224326A (en) | 1978-09-21 | 1980-09-23 | Eli Lilly And Company | Immunosuppressive agents |
| AU626881B2 (en) | 1988-07-14 | 1992-08-13 | F. Hoffmann-La Roche Ag | Benzofused heterocyclics used as pharmaceuticals |
| WO1996014090A1 (en) | 1994-11-07 | 1996-05-17 | Janssen Pharmaceutica N.V. | Compositions comprising carbazoles and cyclodextrins |
| US8519158B2 (en) * | 2004-03-12 | 2013-08-27 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds and methods |
| BRPI0509745A (pt) * | 2004-04-08 | 2007-09-25 | Topotarget As | compostos de difenil ox-indol-2-ona e seu uso no tratamento de cáncer |
| CA2570884C (en) | 2004-06-16 | 2016-04-19 | Jack Arbiser | Carbazole formulations for the treatment of psoriasis and angiogenesis |
| GB0513702D0 (en) * | 2005-07-04 | 2005-08-10 | Sterix Ltd | Compound |
| EP1993535A4 (en) | 2006-03-02 | 2011-04-20 | Glaxosmithkline Llc | THIAZOLONE AS A PI3 KINASE INHIBITOR |
| US20100130579A1 (en) | 2006-10-23 | 2010-05-27 | Georgetown University | Cancer therapy |
-
2010
- 2010-10-25 EA EA201290208A patent/EA201290208A1/ru unknown
- 2010-10-25 KR KR1020127013113A patent/KR20120095402A/ko not_active Withdrawn
- 2010-10-25 GE GEAP201012711A patent/GEP20146138B/en unknown
- 2010-10-25 JP JP2012535441A patent/JP2013508417A/ja active Pending
- 2010-10-25 BR BR112012009262A patent/BR112012009262A2/pt not_active IP Right Cessation
- 2010-10-25 US US13/501,566 patent/US8835447B2/en not_active Expired - Fee Related
- 2010-10-25 EP EP10825802.1A patent/EP2490531A4/en not_active Withdrawn
- 2010-10-25 CN CN2010800474879A patent/CN102573472A/zh active Pending
- 2010-10-25 CA CA2779309A patent/CA2779309A1/en not_active Abandoned
- 2010-10-25 MX MX2012004624A patent/MX2012004624A/es not_active Application Discontinuation
- 2010-10-25 AU AU2010310477A patent/AU2010310477A1/en not_active Abandoned
- 2010-10-25 AP AP2012006277A patent/AP2012006277A0/xx unknown
- 2010-10-25 WO PCT/US2010/053916 patent/WO2011050353A1/en not_active Ceased
-
2012
- 2012-04-10 ZA ZA2012/02557A patent/ZA201202557B/en unknown
- 2012-04-22 IL IL219331A patent/IL219331A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AP2012006277A0 (en) | 2012-06-30 |
| WO2011050353A8 (en) | 2011-07-14 |
| KR20120095402A (ko) | 2012-08-28 |
| JP2013508417A (ja) | 2013-03-07 |
| EP2490531A4 (en) | 2013-06-19 |
| CN102573472A (zh) | 2012-07-11 |
| MX2012004624A (es) | 2012-08-23 |
| BR112012009262A2 (pt) | 2019-09-24 |
| CA2779309A1 (en) | 2011-04-28 |
| EA201290208A1 (ru) | 2012-10-30 |
| AU2010310477A1 (en) | 2012-05-03 |
| WO2011050353A1 (en) | 2011-04-28 |
| IL219331A0 (en) | 2012-06-28 |
| US20120264771A1 (en) | 2012-10-18 |
| GEP20146138B (en) | 2014-08-11 |
| EP2490531A1 (en) | 2012-08-29 |
| US8835447B2 (en) | 2014-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201202557B (en) | Method for treating androgen receptor positive cancers | |
| GB201022002D0 (en) | Authentication apparatus | |
| GB2468569B (en) | Feeding apparatus | |
| ZA201202299B (en) | Method for decreasing immunigenicity | |
| IL217606A0 (en) | Feeding apparatus | |
| GB0913229D0 (en) | Apparatus for bio-automation | |
| EP2531625A4 (en) | PROCESS FOR PROCESSING FRACTURE MATERIALS | |
| IL218633A0 (en) | Methods for treating psoriasis | |
| PT2493565T (pt) | Método de fornecimento de radioterapia | |
| EP2453896A4 (en) | PROCESS FOR TREATING SCHIZOPHRENIA | |
| GB0922091D0 (en) | Communications apparatus | |
| EP2533781A4 (en) | METHOD FOR THE TREATMENT OF BLOOD CANCER | |
| IL218230A0 (en) | Method of treating cancer | |
| PL2440633T3 (pl) | Sposób pirolizy | |
| PL2516716T3 (pl) | Sposób obróbki prania | |
| PT2509599E (pt) | Processo para o tratamento de cancro pancreático | |
| GB201008313D0 (en) | Feeding apparatus | |
| GB2475133B (en) | Security apparatus | |
| GB201014083D0 (en) | Apparatus for retaining | |
| GB0917301D0 (en) | Forming apparatus | |
| GB2483039B (en) | Method for treating hydrocarbons | |
| GB0907671D0 (en) | Adjuster apparatus | |
| GB201016382D0 (en) | Process for treating an underground formation | |
| GB0908765D0 (en) | Improved apparatus | |
| GB0906963D0 (en) | An improved feed apparatus |